High-frequency rTMS improves quality of life and depressive symptoms in Parkinson's disease: A case report

Panayiota Michael; Sandra Blythin Constantinou Juhasz; Olympia Evagorou; Lilia Psalta; Georgios Mikellides

doi:10.1016/j.heliyon.2022.e12196

High-frequency rTMS improves quality of life and depressive symptoms in Parkinson's disease: A case report

Panayiota Michael, Sandra Blythin Constantinou Juhasz, Olympia Evagorou, Lilia Psalta, Georgios Mikellides^*

^*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

Abstract

INTRODUCTION: Parkinson's disease (PD) is a common neurodegenerative disorder, characterised by both motor and nonmotor symptoms. There is currently no cure for PD, although there are several treatment options for relieving PD symptoms. Repetitive transcranial magnetic stimulation (rTMS) is a noninvasive brain stimulation therapy that shows promising results for the treatment of PD.

METHODS: Here, we present a patient with PD. We investigated whether an accelerate form of high-frequency (HF) rTMS on the contralateral side to the patient's main difficulties is clinically effective in treating health-related quality of life (QoL) symptomatology and depressive symptoms in PD as well as the long-term effects of rTMS in PD during the maintenance phase.

RESULTS: Results showed that HF-rTMS administered over the right primary motor cortex (M1) is a safe and well-tolerated treatment that improved the patient's health related QoL and depressive symptoms. These positive effects lasted at least five months post treatment.

CONCLUSION: Therefore, HF-rTMS over the right M1 can be a possible treatment option for patients with PD, although further investigations are necessary to validate the findings of the present case report.

Original language	English
Pages (from-to)	e12196
Number of pages	6
Journal	Heliyon
Volume	8
Issue number	12
DOIs	https://doi.org/10.1016/j.heliyon.2022.e12196
Publication status	Published - Dec 2022

Access to Document

10.1016/j.heliyon.2022.e12196Licence: CC BY

Cite this

@article{c3e8e206dd704c888b80db61f83ceced,

title = "High-frequency rTMS improves quality of life and depressive symptoms in Parkinson's disease: A case report",

abstract = "INTRODUCTION: Parkinson's disease (PD) is a common neurodegenerative disorder, characterised by both motor and nonmotor symptoms. There is currently no cure for PD, although there are several treatment options for relieving PD symptoms. Repetitive transcranial magnetic stimulation (rTMS) is a noninvasive brain stimulation therapy that shows promising results for the treatment of PD.METHODS: Here, we present a patient with PD. We investigated whether an accelerate form of high-frequency (HF) rTMS on the contralateral side to the patient's main difficulties is clinically effective in treating health-related quality of life (QoL) symptomatology and depressive symptoms in PD as well as the long-term effects of rTMS in PD during the maintenance phase.RESULTS: Results showed that HF-rTMS administered over the right primary motor cortex (M1) is a safe and well-tolerated treatment that improved the patient's health related QoL and depressive symptoms. These positive effects lasted at least five months post treatment.CONCLUSION: Therefore, HF-rTMS over the right M1 can be a possible treatment option for patients with PD, although further investigations are necessary to validate the findings of the present case report.",

author = "Panayiota Michael and {Constantinou Juhasz}, {Sandra Blythin} and Olympia Evagorou and Lilia Psalta and Georgios Mikellides",

note = "{\textcopyright} 2022 The Author(s).",

year = "2022",

month = dec,

doi = "10.1016/j.heliyon.2022.e12196",

language = "English",

volume = "8",

pages = "e12196",

journal = "Heliyon",

issn = "2405-8440",

publisher = "Elsevier BV",

number = "12",

}

TY - JOUR

T1 - High-frequency rTMS improves quality of life and depressive symptoms in Parkinson's disease

T2 - A case report

AU - Michael, Panayiota

AU - Constantinou Juhasz, Sandra Blythin

AU - Evagorou, Olympia

AU - Psalta, Lilia

AU - Mikellides, Georgios

PY - 2022/12

Y1 - 2022/12

N2 - INTRODUCTION: Parkinson's disease (PD) is a common neurodegenerative disorder, characterised by both motor and nonmotor symptoms. There is currently no cure for PD, although there are several treatment options for relieving PD symptoms. Repetitive transcranial magnetic stimulation (rTMS) is a noninvasive brain stimulation therapy that shows promising results for the treatment of PD.METHODS: Here, we present a patient with PD. We investigated whether an accelerate form of high-frequency (HF) rTMS on the contralateral side to the patient's main difficulties is clinically effective in treating health-related quality of life (QoL) symptomatology and depressive symptoms in PD as well as the long-term effects of rTMS in PD during the maintenance phase.RESULTS: Results showed that HF-rTMS administered over the right primary motor cortex (M1) is a safe and well-tolerated treatment that improved the patient's health related QoL and depressive symptoms. These positive effects lasted at least five months post treatment.CONCLUSION: Therefore, HF-rTMS over the right M1 can be a possible treatment option for patients with PD, although further investigations are necessary to validate the findings of the present case report.

AB - INTRODUCTION: Parkinson's disease (PD) is a common neurodegenerative disorder, characterised by both motor and nonmotor symptoms. There is currently no cure for PD, although there are several treatment options for relieving PD symptoms. Repetitive transcranial magnetic stimulation (rTMS) is a noninvasive brain stimulation therapy that shows promising results for the treatment of PD.METHODS: Here, we present a patient with PD. We investigated whether an accelerate form of high-frequency (HF) rTMS on the contralateral side to the patient's main difficulties is clinically effective in treating health-related quality of life (QoL) symptomatology and depressive symptoms in PD as well as the long-term effects of rTMS in PD during the maintenance phase.RESULTS: Results showed that HF-rTMS administered over the right primary motor cortex (M1) is a safe and well-tolerated treatment that improved the patient's health related QoL and depressive symptoms. These positive effects lasted at least five months post treatment.CONCLUSION: Therefore, HF-rTMS over the right M1 can be a possible treatment option for patients with PD, although further investigations are necessary to validate the findings of the present case report.

U2 - 10.1016/j.heliyon.2022.e12196

DO - 10.1016/j.heliyon.2022.e12196

M3 - Article

C2 - 36568654

SN - 2405-8440

VL - 8

SP - e12196

JO - Heliyon

JF - Heliyon

IS - 12

ER -